Latest news with #Krull
USA Today
05-03-2025
- Sport
- USA Today
Broncos place 1-year ERA tender on tight end Lucas Krull
Broncos place 1-year ERA tender on tight end Lucas Krull The Denver Broncos placed one-year tenders on all five of their exclusive rights free agents on Tuesday, including tight end Lucas Krull. The ERFA tenders are worth the league minimum. For a player with two years of experience like Krull, that's $1,030,000. That marks a raise from the $915,000 Krull earned last season, but the contract is not guaranteed, so it provides little assurance of making the team. Krull (6-6, 260 pounds) entered the league as an undrafted free agent out of Pittsburgh with the New Orleans Saints in 2022. After spending his rookie season on their practice squad, Krull was cut by the Saints following training camp in 2023. Krull then joined Denver's practice squad and he ended up dressing for seven games that season. Krull appeared in 13 games last fall, hauling in 19 receptions for 152 yards. Through two seasons (20 games) with the Broncos, Krull has totaled 27 catches for 247 yards and one touchdown. He'll now get another chance to compete for a role this summer. In addition to Krull, Denver also placed one-year ERFA tenders on cornerback Ja'Quan McMillian, pass rusher Dondrea Tillman, defensive lineman Jordan Jackson and safety Devon Key. We are tracking all of the team's free agency moves on Broncos Wire. These 25 celebrities are Broncos fans
CBS News
09-02-2025
- Health
- CBS News
Texas A&M study aims to help dogs live longer – and possibly humans too
FORT WORTH — A new study is exploring ways to extend the lifespan of dogs, potentially paving the way for similar treatments in humans. The Dog Aging Project, led by researchers at Texas A&M and the University of Washington, is studying canine aging with a focus on the drug rapamycin, commonly used during human organ transplants. Early studies suggest the drug may improve heart and cognitive function, mobility and even extend a dog's lifespan. Dr. Kate Creevy, co-founder of the project, emphasized that while the drug isn't a miracle cure, the goal is to help dogs not only live longer but also remain healthier in their later years. "This is a really important example of community science," Creevy said. "The people collecting this data are dog owners, everyday folks. Science doesn't have to happen in some ivory tower or a research institution. Science is happening every day all around us." So far, 170 dogs are participating in the trial. With a new $7 million federal grant, researchers hope to expand the study to 580 dogs. If successful, the research could provide insights into extending human lifespan as well. Ron Beiswanger, a North Texas dog owner, enrolled his 9-year-old pit bull, Krull, in the study two years ago. He won't know until the study concludes whether Krull has been receiving rapamycin or a placebo, but he has no regrets about taking part. "They're only here for a short time, and it's not fair to us," Beiswanger said. "The longer they are here, the better. If I can be a statistic to help future dogs, this is worth it." Results from the study are expected in about four years. Dog owners interested in enrolling their pets in the trial must have dogs over 7 years old, in good health, and weighing at least 44 pounds. Owners will also need to bring their dogs to one of the participating clinical sites, such as Texas A&M, every six months for three years.
CBS News
07-02-2025
- Health
- CBS News
A&M study aims to help dogs live longer – and maybe humans too
FORT WORTH — A new study is exploring ways to extend the lifespan of dogs, potentially paving the way for similar treatments in humans. The Dog Aging Project, led by researchers at Texas A&M and the University of Washington, is studying canine aging with a focus on the drug rapamycin, commonly used during human organ transplants. Early studies suggest the drug may improve heart and cognitive function, and mobility, and even extend a dog's lifespan. Dr. Kate Creevy, co-founder of the project, emphasizes that while the drug isn't a miracle cure, the goal is to help dogs not only live longer but also remain healthier in their later years. "This is a really important example of community science," Creevy said. "The people collecting this data are dog owners, everyday folks. Science doesn't have to happen in some ivory tower or a research institution. Science is happening every day all around us." So far, 170 dogs are participating in the trial. With a new $7 million federal grant, researchers hope to expand the study to 580 dogs. If successful, the research could provide insights into extending human lifespan as well. Ron Beiswanger, a North Texas dog owner, enrolled his 9-year-old pit bull, Krull, in the study two years ago. He won't know until the study concludes whether Krull has been receiving rapamycin or a placebo, but he has no regrets about taking part. "They're only here for a short time, and it's not fair to us," Beiswanger said. "The longer they are here, the better. If I can be a statistic to help future dogs, this is worth it." Results from the study are expected in about four years. Dog owners interested in enrolling their pets in the trial must have dogs over 7 years old, in good health, and weighing at least 44 pounds. Owners will also need to bring their dogs to one of the participating clinical sites, such as Texas A&M, every six months for three years.
